Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The PPHM board members where upset at a ASM because of all the posts about them on IHub. PPHM shareholders should attend them every once in a while.
djohn, you are a wise man. KNOWLEDGE has to be accompanied and complemented by WISDOM :)
Bio, great list. The numbers on the list is another reason that the PPHM management should not play "hard to get" with major BPs that are interested in PPHM and that are also working with hundreds of biotechs with new classes of drugs. In the PPHM case, Bread crumps in a partnership with BP can become a bakery full of different loafs of bread in no time :)
Andy, I don't profess to be anything. In a nut shell, I was in the biotech industry for almost 20 years and worked for two of the best, Genentech and Biogen IDEC and saw where they started and where they got because of good management. PPHM BOD read this board everyday and I just want to remind them how much they make for their non-performance (they have been on the board for over 20 years). That's all. No disrespect to shareholders
Yes. Just like our double stud CONSULTANT Garnick. I wonder how much he made off of us shareholders. He is probably sitting in one of Roche's yachts out for a summer cruise :)
I wonder how all the :) "enrolled patients" :) in the two phase I studies that we have been talking about for a year now are doing ?
LOL. Steve King has been in "partnering discussions" for the 17 years that I have been around.
Imagine having a test that can tell patients 100% if they have ovarian cancer and the stage of it and then sit on it for months after months. Can GREED become that strong ?
Carlton Johnson: $350,000 a year
David Pohl: $290,000 a year
Eric Swartz: $320,000 a year
For sitting in on a few conference calls.
Biopharm, good points. However, your shares will be divided by 7 this coming week and you will never find out what the BOD presented to NASDAQ
Corporate Board Members are SUPPOSE to be independent of each other. Look up the history of PPHM board members business relationships with each other
PPHM Board of Directors and yes that is you Carlton
Thanks IFU
Carlton Johnson:
"No Idea How He Got the Job, definitely wasn't not due to experience"
$350,000 a year
David Pohl:
"Probably says, OMG I am so lucky to have this job because I have no experience at all. Good to know Eric Swartz"
$290,000 a year
Eric Swartz:
"I paid to have this Job and will put my Lawyer as a Puppet COB, Life is Good"
$320,000 a year
Just for sitting in on a few conference calls. Would love any law suits to make them perform of get removed.
You are hearing this logic from someone that worked for Genentech when they partnered and were saved by Roche and worked for IDEC when they partnered and were saved by Genentech. I retired at 45. PPHM could be Genentech right now under qualified leadership.
Jeff4,
my logic is based on the facts that I have been reading for YEARS about Bavi and the science behind PS targeting and Bavi.
Now keep aside the share price before and after a reverse split and just think that the share price is valued at $10 based on the SCIENCE and the potential of the BAVI science.
Now imagine the value of your PPHM stock if it goes to $10 after a Reverse split caused by lack of performance (i.e. partnering) of 3 unqualified board members that make over 300 thousand dollars a year for sitting in on a few conference calls:
Based on all the speeches and links that are given on this board, if a substantial partnership with a big player happens and the stock goes to lets say $10
If you have 7000 shares
Pre Split: 7000 X $10 = $70,000
After Reverse Split: 1000 X $10 = $10,000
Wook, a lot of us look at it this way:
Based on all the speeches and links that are given on this board, if a substantial partnership with a big player happens and the stock goes to lets say $10
If you have 7000 shares
Pre Split: 7000 X $10 = $70,000
After Reverse Split: 1000 X $10 = $10,000
Very Simple
Calculator not needed
It is not Bavi ! "It is the Board of Directors stupid !" said the way Bill Clinton said it
If the PPHM BOD does not want a deal to happen so that they can keep their gig, no partnership will happen,
If the PPHM BOD wants a Reverse Split to decrease the number of shareholders share and keep using the ATM, then all they have to say to NASDAQ is that they are going to be profitable in 12 months which will not do the job.
Making a few million from manufacturing and call it profitability does not do anything in this industry. Profitability is measured by hundreds of millions from selling drugs in this business.
We will never know what this BOD presented to NASDAQ
Now lets divide our shares by 7
Very Simple
Refresh my memory how much money we, including yourself have lost so far.
We have been talking about
IPs
PS
Beta Bodies
Now Exosomes
Trade Marks
Secret Negotiations
Secret Strategies
Collaborations, KOLs, Genius consultant Garnick
Secret Families, Secret accumulations
Avids and on and on and on
for years. This stock is going thru a Reverse Split. Meaning 1 share for 7 of our hard earning shares and will stay here as long as the following applies
Carlton Johnson:
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
For sitting in on a few conference calls.
Happy Long Chatting
Horselover, That is not called "negative side of anything". It is called, "REALITY". Look up the share price for one year. Shareholder positive thoughts does not work in this situation.
Patiently, do you really think that the following board members are going to go thru all this trouble when they have the approval for Reverse Split. Everything that they are doing right now including the drug names is to prevent a law suit or chances of a law suit against them winning.
Carlton Johnson:
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
For sitting in on a few conference calls
And the industry moves on. 1 share for 7 of our shares coming up. The following are not going to let their present gig go.
https://www.yahoo.com/beauty/m/d41fa62d-19b0-3702-9be6-9fddee6d8fde/ss_fda-approves-cancer-drug-for.html
Carlton Johnson:
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
For sitting in on a few conference calls
Biopharm,
NASDAQ did not force them to file an appeal. Therefore, they can present whatever they want. If the following BOD members want a Reverse Split to stay in power all they have to do is to say that they are going to be profitable in 12 months which will not do the job.
Us shareholders will never know what they actually presented.
Carlton Johnson:
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
This stock is getting all nice and ready for a Reverse Split. Go PS exposure Go
Upcoming PPHM Events:
1) Reverse Split: 1 share for 7 of your shares that is a NEUTRAL event
2) Filing of multiple law suits which is a NATURAL event
3) News blackout by the following board members for the infamous reason, "CAN'T SAY ANYTHING DURING CA" event
Carlton Johnson:
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
Biopharm,
For PPHM shares to go up they need to sell a drug or diagnostic test to bring in money. In order to do that your product need to go thru intensive clinical trials.
No number of collaborations is going to do the job of getting the drug approved. Collaborations in our case could even mean the system trying to slow down PPHM which they don't need help on with this BOD.
You can puzzle piece all day long but without a major partner we are not going to go anywhere. We announced couple of studies 9 months ago and we have not enrolled a patient yet.
We have a test that tells whether someone has ovarian cancer and we are sitting on it. Bread crumps is much better than 2 RS and stock under 60 cents.
This BOD is not going to let their current gig go
Stroke of Genius is to make:
Carlton Johnson:
"No Idea How He Got the Job, definitely wasn't due to experience"
$350,000 a year
David Pohl:
"Probably says, OMG I am so lucky to have this job because I have no experience at all. Good to know Eric Swartz"
$290,000 a year
Eric Swartz:
"I paid to have this Job and will put my Lawyer as a Puppet COB, Life is Good"
$320,000 a year
Sitting in on a few conference calls
They are not going to let this gig go anywhere anytime soon
5020 abstracts will be released today with one of them being PPHM's. It will probably talk about a biomarker like exosomes which the following 3 board members will do nothing with in the foreseen future.
Carlton Johnson:
$350,000
David Pohl:
$290,000
Eric Swartz:
$320,000
PS and Exosomes are great science. 3 Board Members are what is going to keep PPHM stock were it is. Happy chatting day to all.
Carlton Johnson
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
Will the 3 unqualified BOD members let the following go after 20 years?
Carlton Johnson
$350,000 a year
David Pohl:
$290,000 a year
Eric Swartz:
$320,000 a year
Plus many many options for sitting in on a few conference calls for 20 years.
Answer: 3,2,1.... BIG NO
3 PPHM BOD members collect 320 Thousand Dollars a year sitting in on a few conference calls
What is so hard about understanding that no amount of PS papers and scientists working on it is going to take PPHM anywhere unless the 3 people with 320 thousand dollar a year paycheck for sitting at home and having a choke hold on this company let it go.
The BPs are making billions already and are not going to do any begging to 3 unqualified board members.
Now 3,2,1 RS or is it a cup on the chart with no handle after the market and with handle pre market ?
CP, here is my opinion regarding the appeal
1) PPHM had to file an appeal by April 20
2) I am assuming PPHM had to present something for the nasdaq to bother putting a committee together
3) After that nasdaq has up to 45 days to set a face to face meeting and decide on extension
Even if they did not present a case on april 20, they have to present it at the day of the meeting and I want to know exactly what they presented.
Now if this BOD wants a RS, all they have to say is that we are planning to be profitable in 12 months which will not do the job.
Bottom line is after 17 years I do not TRUST this BOD because they are GREEDY and I have seen them perform or lack of perform in many ASMs. And don't tell me about collaborations and all of that because the pphm employees and outside scientists are doing all the planning and work for probably less than 320 thousands dollars a year. By the way, some people keep justifying their secrecy which is making them bolder.
Very Simple
Biopharm, you should try to find the puzzle piece that says Exactly what PPHM presented to NASDAQ appeal team. I think as stockholders that might go thru a second Reverse Split we need to know that. And don't tell me it contains classified information that they can't share with us. We already listened to "silence because of Class Action suit" tune before.
So sad that we talk about pennies up pennies down all day long on this board while the little biotechs move on with the help of a big BP brother. Wonder what the v or u charts look like these days.
None of us will ever find out what they presented to NASDAQ
Biopharm, Divide your shares by 7
Alright everybody, I think we should all start dividing our shares by 7 and get used to the idea.
PS targeting and Exosomes are not going to go anywhere anytime soon under this management team. Remember, 320 thousand dollars a piece for 3 board members that don't do much. They will try to keep it as long as they can.
Now, lets talk about PS all day long while other biotechs are moving on, making money and saving lives.
PPHM Facts and Questions
Facts:
Bavi is a valid drug that has proved that it works well with chemotherapy, radiotherapy and immunotherapy.
Bavi now has the backing of many well known scientists
Bavi also works well fighting certain infectious diseases.
Exosome test can revolutionize the cancer detection and follow up in the diagnostics field.
Avid I, II and III can be the best asset a BP can have.
Three of the PPHM BOD members with no Pharmaceuticals experience have been on the board for 20 years making 320 thousand dollars a year just having to attend a ASM and seat on a few conference calls.
Questions:
Would such a BOD be in a hurry to jeopardize the big pay and the power that they have over that big pay any time soon by partnering with a pharmaceutical company ?
Is the price and the TERMS that they are asking for realistic at this point or just a way to document that they are trying ?
Is a RS beneficial to them to keep their seats, pay and power and the appeal is just to keep the shareholders quiet and prevent law suits ?
Will we as shareholders ever find out what they actually presented to the NASDAQ appeal panel ?
AGAIN, we can talk about how great Bavi is ALL day long. The issue here is when it stops curing mice and starts to be in hundreds of clinical trials thru a major partner ?